
June 6 (Reuters) - The European Medicines Agency's (EMA) safety committee has concluded that a potentially dangerous eye condition is a very rare side effect of Novo Nordisk's NOVOb.CO popular treatments Ozempic and Wegovy, it said on Friday.
The condition may affect up to 1 in 10,000 people taking semaglutide, the chemical name for Wegovy and Ozempic, the EMA said.